Information de reference pour ce titreAccession Number: | 01451459-201409150-00006.
|
Author: | Ye, Jing 1,2,a; Jiang, Rong 1,2,a; Cui, Min 1,2; Zhu, Bibo 1,2; Sun, Leqiang 1,2; Wang, Yueyun 1,2; Zohaib, Ali 1,2; Dong, Qian 1,2; Ruan, Xindi 1,2; Song, Yunfeng 1,2; He, Wen 1,2; Chen, Huanchun 1,2; Cao, Shengbo 1,2
|
Institution: | (1)State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University (2)College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei, P.R China
|
Title: | |
Source: | Journal of Infectious Diseases. 210(6):875-889, September 15, 2014.
|
Abstract: | Background. Japanese encephalitis virus (JEV) is a neurotropic flavivirus that causes Japanese encephalitis (JE), which leads to high fatality rates in human. Tumor necrosis factor alpha (TNF-[alpha]) is a key factor that mediates immunopathology in the central nervous system (CNS) during JE. Etanercept is a safe anti-TNF-[alpha] drug that has been commonly used in the treatment of various human autoimmune diseases.
Methods. The effect of etanercept on JE was investigated with a JEV-infected mouse model. Four groups of mice were assigned to receive injections of phosphate-buffered saline, etanercept, JEV, or JEV plus etanercept. Inflammatory responses in mouse brains and mortality of mice were evaluated within 23 days post infection.
Results. The in vitro assay with mouse neuron/glia cultures showed that etanercept treatment reduced the inflammatory response induced by JEV infection. In vivo experiments further demonstrated that administration of etanercept protected mice from JEV-induced lethality. Neuronal damage, glial activation, and secretion of proinflammatory cytokines were found to be markedly decreased in JEV-infected mice that received etanercept treatment. Additionally, etanercept treatment restored the integrity of the blood-brain barrier and reduced viral load in mouse brains.
Conclusions. Etanercept effectively reduces the inflammation and provides protection against acute encephalitis in a JEV-infected mouse model.
(C) Copyright Oxford University Press 2014.
|
Author Keywords: | etanercept; Japanese encephalitis virus; viral encephalitis; TNF-[alpha]; inflammation.
|
References: | 1. Misra UK, Tan CT, Kalita J. Viral encephalitis and epilepsy Epilepsia. 2008;49(Suppl 6):13-8
2. Ghosh D, Basu A. Japanese encephalitis-a pathological and clinical perspective PLoS Negl Trop Dis. 2009;3:e437
3. Gupta N, Santhosh SR, Babu JP, Parida MM, Rao PV. Chemokine profiling of Japanese encephalitis virus-infected mouse neuroblastoma cells by microarray and real-time RT-PCR: implication in neuropathogenesis Virus Res. 2010;147:107-12
4. Ghoshal A, Das S, Ghosh S, et al. Proinflammatory mediators released by activated microglia induces neuronal death in Japanese encephalitis Glia. 2007;55:483-96
5. Harms AS, Lee JK, Nguyen TA, et al. Regulation of microglia effector functions by tumor necrosis factor signaling Glia. 2012;60:189-202
6. Smith JA, Das A, Ray SK, Banik NL. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases Brain Res Bull. 2012;87:10-20
7. Ravi V, Parida S, Desai A, Chandramuki A, Gourie-Devi M, Grau GE. Correlation of tumor necrosis factor levels in the serum and cerebrospinal fluid with clinical outcome in Japanese encephalitis patients J Med Virol. 1997;51:132-6
8. Liebert UG. Slow and persistent virus infections of neurones-a compromise for neuronal survival Curr Top Microbiol Immunol. 2001;253:35-60
9. Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence Epilepsia. 2005;46:1724-43
10. de Vries HE, Blom-Roosemalen MC, van Oosten M, et al. The influence of cytokines on the integrity of the blood-brain barrier in vitro J Neuroimmunol. 1996;64:37-43
11. Fiala M, Looney DJ, Stins M, et al. TNF-alpha opens a paracellular route for HIV-1 invasion across the blood-brain barrier Mol Med. 1997;3:553-64
12. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, Flavell RA. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis Nat Med. 2004;10:1366-73
13. Samuel MA, Diamond MS. Pathogenesis of West Nile virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion J Virol. 2006;80:9349-60
14. Keller CW, Fokken C, Turville SG, et al. TNF-alpha induces macroautophagy and regulates MHC class II expression in human skeletal muscle cells J Biol Chem. 2011;286:3970-80
15. Kramer K, Schaudien D, Eisel UL, et al. TNF-overexpression in Borna disease virus-infected mouse brains triggers inflammatory reaction and epileptic seizures PloS One. 2012;7:e41476
16. Chen CJ, Ou YC, Lin SY, et al. Glial activation involvement in neuronal death by Japanese encephalitis virus infection J Gen Virol. 2010;91:1028-37
17. Rappaport J, Joseph J, Croul S, et al. Molecular pathway involved in HIV-1-induced CNS pathology: role of viral regulatory protein, Tat J Leukoc Biol. 1999;65:458-65
18. Jazwinski AB, Jezsik J, Ardoin SP, McCallum RM, Tillmann HL. Etanercept treatment to enable successful hepatitis C virus clearance in a patient with rheumatoid arthritis Gastroenterol Hepatol (N Y). 2011;7:772-4
19. Venegas-Pont M, Manigrasso MB, Grifoni SC, et al. Tumor necrosis factor-alpha antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus Hypertension. 2010;56:643-9
20. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis Lancet. 1994;344:1125-7
21. Zou JX, Braun J, Sieper J. Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment Clin Exp Rheumatol. 2002;20:S34-7
22. Lin J, Ziring D, Desai S, et al. TNFalpha blockade in human diseases: an overview of efficacy and safety Clin Immunol. 2008;126:13-30
23. Cassano N, Mastrandrea V, Principi M, et al. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease J Biol Regul Homeost Agents. 2011;25:285-9
24. Giannini EH, Ilowite NT, Lovell DJ, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis Arthritis Rheum. 2009;60:2794-804
25. Wu YP, Chang CM, Hung CY, Tsai MC, Schuyler SC, Wang RY. Japanese encephalitis virus co-opts the ER-stress response protein GRP78 for viral infectivity Virol J. 2011;8:128
26. Hodgetts S, Radley H, Davies M, Grounds MD. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with etanercept in mdx mice Neuromuscul Disord. 2006;16:591-602
27. Zaid A, Rulli NE, Rolph MS, Suhrbier A, Mahalingam S. Disease exacerbation by etanercept in a mouse model of alphaviral arthritis and myositis Arthritis Rheum. 2011;63:488-91
28. Sehgal N, Kumawat KL, Basu A, Ravindranath V. Fenofibrate reduces mortality and precludes neurological deficits in survivors in murine model of Japanese encephalitis viral infection PloS One. 2012;7:e35427
29. Mishra MK, Basu A. Minocycline neuroprotects, reduces microglial activation, inhibits caspase 3 induction, and viral replication following Japanese encephalitis J Neurochem. 2008;105:1582-95
30. Chen CJ, Ou YC, Chang CY, et al. TNF-alpha and IL-1beta mediate Japanese encephalitis virus-induced RANTES gene expression in astrocytes Neurochem Int. 2011;58:234-42
31. Chen CJ, Ou YC, Chang CY, et al. Glutamate released by Japanese encephalitis virus-infected microglia involves TNF-alpha signaling and contributes to neuronal death Glia. 2012;60:487-501
32. Shrestha B, Zhang B, Purtha WE, Klein RS, Diamond MS. Tumor necrosis factor alpha protects against lethal West Nile virus infection by promoting trafficking of mononuclear leukocytes into the central nervous system J Virol. 2008;82:8956-64
33. Szretter KJ, Samuel MA, Gilfillan S, et al. The immune adaptor molecule SARM modulates tumor necrosis factor alpha production and microglia activation in the brainstem and restricts West Nile Virus pathogenesis J Virol. 2009;83:9329-38
34. Lundberg P, Welander PV, Edwards CK 3rd, van Rooijen N, Cantin E. Tumor necrosis factor (TNF) protects resistant C57BL/6 mice against herpes simplex virus-induced encephalitis independently of signaling via TNF receptor 1 or 2 J Virol. 2007;81:1451-60
35. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma Thorax. 2005;60:1012-8
36. Forrest EH, Oien KA, Dickson S, Galloway D, Mills PR. Improvement in cholestasis associated with total parenteral nutrition after treatment with an antibody against tumour necrosis factor alpha Liver. 2002;22:317-20
37. Bell S, Kamm MA. Antibodies to tumour necrosis factor alpha as treatment for Crohn's disease Lancet. 2000;355:858-60
38. Genovese T, Mazzon E, Crisafulli C, et al. Immunomodulatory effects of etanercept in an experimental model of spinal cord injury J Pharmacol Exp Ther. 2006;316:1006-16
39. Korner H, Lemckert FA, Chaudhri G, Etteldorf S, Sedgwick JD. Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system Eur J Immunol. 1997;27:1973-81
40. Campbell SJ, Jiang Y, Davis AE, et al. Immunomodulatory effects of etanercept in a model of brain injury act through attenuation of the acute-phase response J Neurochem. 2007;103:2245-55
|
Language: | English.
|
Document Type: | MAJOR ARTICLES AND BRIEF REPORTS.
|
ISSN: | 0022-1899
|
DOI Number: | https://dx.doi.org/10.1093/infdi...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|